Literature DB >> 6403323

[Doppler ultrasound studies of the extracranial cerebral vessels in migraine patients after ergotamine tartrate administration].

R Puzich, W Girke, H Heidrich, M Rischke.   

Abstract

Doppler ultrasound investigations were done in 20 patients with migraine during the symptom-free interval after oral administration of 2 mg and 6 mg ergotamine tartrate. The observed changes of end-diastolic flow velocity as a measure of peripheral total resistance permit simultaneous assessment of the vasoconstrictor effect of ergotamine in the perfusion area of the internal and external carotid arteries. A dosage of 2 mg led to an exclusive increase of resistance in the external carotid artery area without significant changes in the internal carotid area. A maximal therapeutic dosage of 6 mg ergotamine tartrate did not lead to a significant increase of the vasoconstrictor effect in the external carotid circulation. In addition, a barely registrable increase of resistance in the internal carotid area could now be observed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6403323     DOI: 10.1055/s-2008-1069578

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  4 in total

Review 1.  Pharmacology of antimigraine drugs.

Authors:  P R Saxena; M O Den Boer
Journal:  J Neurol       Date:  1991       Impact factor: 4.849

Review 2.  Clinical pharmacokinetics of ergotamine in migraine and cluster headache.

Authors:  V L Perrin
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

3.  Ergotamine, flunarizine and sumatriptan do not change cerebral blood flow velocity in normal subjects and migraneurs.

Authors:  H C Diener; C Peters; M Rudzio; A Noe; J Dichgans; R Haux; R Ehrmann; P Tfelt-Hansen
Journal:  J Neurol       Date:  1991-08       Impact factor: 4.849

4.  Reduction of cephalic arteriovenous shunting by ergotamine is not mediated by 5-HT1-like or 5-HT2 receptors.

Authors:  A H Bom; J P Heiligers; P R Saxena; P D Verdouw
Journal:  Br J Pharmacol       Date:  1989-06       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.